Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TAOK1 | Q7L7X3 | 4/20 | 0.52 |
| ▸ | TAOK3 | Q9H2K8 | 3/20 | 0.52 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31458292 | 0.81 | ALDH1A1 (0.57) | RAB9ATAOK1TAOK3P2RY12 | |
| SCHEMBL5654808 | 0.81 | ALDH1A1 (0.57) | RAB9ATAOK1TAOK3P2RY12 | |
| SCHEMBL13983486 | 0.79 | KMT2A (0.62) | MAPTKMT2ARAB9APOLBP2RY12 | |
| SCHEMBL31458352 | 0.79 | ALDH1A1 (0.69) | MAPTKMT2ARAB9AKDM4ETAOK1 | |
| SCHEMBL5653764 | 0.79 | ALDH1A1 (0.69) | MAPTKMT2ARAB9AKDM4ETAOK1 | |
| SCHEMBL27629593 | 0.78 | KMT2A (0.71) | MAPTKMT2ALMNASLC6A7MEN1 | |
| SCHEMBL4489544 | 0.77 | KMT2A (0.75) | MAPTKMT2ARAB9AKDM4ELMNA | |
| SCHEMBL1222690 | 0.77 | KMT2A (0.60) | KMT2ARAB9ALMNASLC6A7MEN1 | |
| SCHEMBL13058919 | 0.76 | RAB9A (0.59) | KMT2ARAB9AKDM4ELMNA | |
| SCHEMBL1222363 | 0.76 | KMT2A (0.77) | MAPTKMT2AKDM4ELMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | claimed |
| US-20250354151-A1 | INHIBITORY AGENT FOR MYOCARDIAL CELL DEATH, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR MYOCARDIAL DISORDERS OR HEART FAILURE | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2025-11-20 | — | — | US | disclosed |
| EP-4534091-A1 | INHIBITORY AGENT FOR MYOCARDIAL CELL DEATH, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR MYOCARDIAL DISORDERS OR HEART FAILURE | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250354151-A1 | INHIBITORY AGENT FOR MYOCARDIAL CELL DEATH, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR MYOCARDIAL DISORDERS OR HEART FAILURE | TNNI3, TNNC1, TNNT2 | MAPT 4762/4885KMT2A 4683/4885RAB9A 4119/4885 |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | TAOK1, TAOK3, MAP3K6 | MAPT 4207/4885KMT2A 2240/4885RAB9A 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.